Alphatec ups FY25 revenue view to $763.4M-$764.4M from $760M, consensus $760.4M

The company said, “Preliminary total revenue grew approximately 25% in the full year 2025. Strong surgeon adoption drove full-year 2025 surgical revenue growth of 26% with surgical volume growth of 24% and average revenue per procedure growth of 2%. Strong revenue growth continues to drive leverage, and the Company re-affirms its full-year 2025 adjusted EBITDA guidance of $91 million. Cash balance as of December 31, 2025, approximated $161 million and the Company continues to expect fourth-quarter free cash flow in the range of $6 million to $8 million.”